TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10378327
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of proximal deep vein thrombosis or symptomatic pulmonary embolism and permanent/unknown triggering factor
Study: 10378327
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of cardiolipin antibodies
Study: 6133575
Drug: Aversion-relief therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aversion-relief therapy
Study: 30113559
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral cochlear implantation with a 2‐year interimplant interval
Study: 26955768
Drug: Succinylcholine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine administration during rapid sequence induction (RSI) for general anesthesia
Study: 22248711
Drug: Pegfilgrastim (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (single subcutaneous injection at day 5)
Study: 22248711
Drug: Filgrastim (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (daily injections from day 5 until recovery of ANC to 0.5 G/L)
Study: 19439949
Drug: Conventional dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional dentifrice (1,100 microg F/g)
Study: 19439949
Drug: Low-F dentifrice
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-F dentifrice (500 microg F/g)
Study: 17617747
Drug: Ranolazine 750
Normalized name: Ranolazine 750 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 750 mg or 1000 mg bid
Study: 11205198
Drug: 5-fluorouracil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5 FU) alone (arm A: 450 mg/m2/day‐5/21 days)
Study: 11205198
Drug: Combined folinic
Normalized name: oxolinic acid
DrugBank: Oxolinic acid (DB13627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined folinic acid (FOL) and 5 FU (arm B: 200 mg/m2 racemic form or 100 mg/m2‐l‐form and 370 mg/m2/day‐5/21 days)
Study: 9315984
Drug: Phenytoin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (200 mg a.m. and 100 mg p.m.)
Study: 3948628
Drug: Octylonium bromide
Normalized name: octylonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octylonium bromide (80 mg, qid, per os) for 5-7 days
Study: 3948628
Drug: IBS patients
Normalized name: Ibsrela
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IBS patients (without treatment)
Study: 31132664
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 20 mg/mL once daily (GA20)
Study: 21253774
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (individually adapted supplements enriched with protein and antioxidants)
Study: 16507859
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 81 mg once daily
Study: 12735583
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (5 mL delivered by aerosolized spraying)
Study: 11054621
Drug: Carvedilol (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (long-term treatment, 4 months)
Study: 11054621
Drug: Carvedilol (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (long-term treatment)
Study: 9076868
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg T.I.D. for 48 hours
Study: 9076868
Drug: Gabapentin higher
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin higher doses (up to 3600 mg/day) during open-label extension
Study: 9076868
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg T.I.D. and 800 mg T.I.D.
Study: 8398955
Drug: Epidural blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blood patch therapy
Study: 8398955
Drug: Fentanyl as
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl as adjunct
Study: 3533203
Drug: No blood
Normalized name: VivaGuard Ino Blood Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: No blood transfusion unless hemoglobin fell below 8 g/dl or patients were shocked (control group)
Study: 23686969
Drug: Cognitive–behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive–behavioral therapy
Study: 17144124
Drug: Indomethacin (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (usual doses)
Study: 10904510
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (12.5 mg/d of chlorthalidone, with possible addition of 25 mg/d of atenolol or 0.05 mg/d of reserpine)
Study: 8439209
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g ampicillin-sulbactam (2 g ampicillin-1 g sulbactam), every 6 hours
Study: 8439209
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin, every 6 hours
Study: 3712636
Drug: Protamine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine (0.75 mg/kg/3 min)
Study: 3712636
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (n = 8)
Study: 18431480
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination with live attenuated yellow fever 17D vaccine at a reduced dose (1/5th; 0.1 mL)
Study: 18431480
Drug: Subcutaneous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vaccination with live attenuated yellow fever 17D vaccine (0.5 mL)
Study: 17205821
Drug: Resolving phlegm
Normalized name: Phleum pratense top
DrugBank: Phleum pratense top (DB14179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resolving phlegm method (RPM) using Chinese herbs (Indigo Naturalis 10 g, Alumen 3 g, Semen Cassiae 15 g, Fructus Crataegi 15 g, vinegar prepared Radix Bupleuri 10 g, Radix Curcumae 10 g, Radix Salviae Miltiorrhizae 12 g, Herba Lycopi 12 g, talc 12 g, Radix Glycyrrhizae 2 g), one dose twice per day orally for 12 weeks
Study: 17205821
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid tablet (UAT) 150 mg three times per day for 12 weeks
Study: 12557834
Drug: Alfentanil 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 40 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Study: 12557834
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Study: 12557834
Drug: Remifentanil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 3 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Study: 12557834
Drug: Remifentanil 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 4 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Study: 8899093
Drug: Lansoprazole plus
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole plus amoxycillin (lansoprazole 30 mg o.m. for 6 or 8 weeks + amoxycillin 500 mg q.d.s. for the first 2 weeks)
Study: 8899093
Drug: Lansoprazole alone
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole alone (30 mg o.m. for 6 or 8 weeks)
Study: 1985415
Drug: High-dosage antioxidants
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage antioxidants (tocopherol and ascorbate)
Study: 29228438
Drug: Low-dose dezocine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dezocine (0.05 mg/kg)
Study: 29228438
Drug: Medium-dose dezocine
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose dezocine (0.1 mg/kg)
Study: 29228438
Drug: High-dose dezocine
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose dezocine (0.15 mg/kg)
Study: 29228438
Drug: Control (fentanyl:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (fentanyl: 10 μg/kg)
Study: 25390761
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg daily (n = 18, 7 males)
Study: 25390761
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg daily (n = 19, 3 males)
Study: 14977896
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravaginal prostaglandin E(2) gel
Study: 9081851
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg micronized form of fenofibrate
Study: 29290275
Drug: Cold gel
Normalized name: Deep Freeze Cold Gel
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold gel pad application for 20 minutes in the postpartum first 2 hours and 4 hours after the first application
Study: 29290275
Drug: Cold gel
Normalized name: Deep Freeze Cold Gel
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold gel pad application
Study: 26317662
Drug: Regular Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Dose of Echinacea-Based Supplement (RD)
Study: 26317662
Drug: Double Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Dose of Echinacea-Based Supplement (DD)
Study: 24673056
Drug: Saturated-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated-dose group (30 cases) - heat-sensitive moxibustion until disappearance of heat-sensitive feeling, treated twice a day for 5 days, then once a day for 30 days.
Study: 24673056
Drug: Traditional-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional-dose group (30 cases) - heat-sensitive moxibustion for 15 minutes each time, treated twice a day for 5 days, then once a day for 30 days.
Study: 20725056
Drug: Atenolol with
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol with added diuretic (second-line therapy)
Study: 20725056
Drug: Amlodipine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine with added perindopril (second-line therapy)
Study: 18303278
Drug: Preventive measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive measures including fluoride varnish applications, mouthrinsing with 0.12% chlorhexine digluconate, professional oral hygiene.
Study: 3621989
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine twice daily
Study: 3621989
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg mefruside once daily
Study: 3621989
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and mefruside
Study: 27217288
Drug: Very brief
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very brief intervention for promoting physical activity in primary care (details on dosage and duration not available)
Study: 25385912
Drug: Gum-chewing (sugarless
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum-chewing (sugarless gum, 3 times daily for 30 min starting 6 hours postoperatively)
Study: 22079797
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg docosahexaenoic acid (G-DHA) daily for 14 days
Study: 22079797
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (G-OO) as placebo for 14 days
Study: 10150489
Drug: Cistinexine dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cistinexine dihydrochloride (active drug)
Study: 1988827
Drug: HA-1A (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1A (100 mg intravenous dose in 3.5 g of albumin)
Study: 1988827
Drug: Placebo (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3.5 g of albumin)
Study: 27400374
Drug: Celecoxib 800
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 800 mg/day for 14 days before surgery
Study: 17233861
Drug: Rapid access
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid access to ultrasound and CA125 test for women with symptoms; no specific dosage or duration mentioned.
Study: 12149108
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg three times a day for 8 weeks)
Study: 9834911
Drug: Isoniazid plus
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid plus rifampin (300 mg isoniazid + 600 mg rifampin per day for 3 months)
Study: 9834911
Drug: Isoniazid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (300 mg per day for 9 months)
Study: 7666798
Drug: Glutamine 0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine 0.28 g/kg BW
Study: 7666798
Drug: Alpha-ketoglutarate 0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-ketoglutarate 0.28 g/kg BW
Study: 7666798
Drug: Control (glucose
Normalized name: INFINITY CONTROL (GLUCOSE) NORMAL CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (glucose 2 g/kg BW)
Study: 30478972
Drug: Traditional speech
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional speech therapy (control group)
Study: 27061732
Drug: Moderate stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate stress during preparation for a medical exam with high-salt intake
Study: 25792627
Drug: Conventional hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional hormone therapy
Study: 25792627
Drug: Ibandronate monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate monthly
Study: 17058239
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg/6 h)
Study: 17058239
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with steroids
Study: 12629535
Drug: GTS‐21 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTS‐21 (25, 75 and 150 mg)
Study: 10853877
Drug: Low-dose ATP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ATP infusion (25-40 microg kg(‐1) min(‐1))
Study: 10853877
Drug: Middle-dose ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose ATP infusion (45-60 microg kg(‐1) min(‐1))
Study: 10853877
Drug: High-dose ATP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ATP infusion (65-75 microg kg(‐1) min(‐1))
Study: 3839973
Drug: Sucralfate (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (6 g per day)
Study: 3839973
Drug: Open sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open sucralfate treatment (after initial placebo)
Study: 12810993
Drug: Cyclosporine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (3 mg/kg/day, increased to 4 mg/kg after two weeks if response was inadequate)
Study: 12810993
Drug: Methotrexate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (0.5 mg/kg weekly)
Study: 1862891
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac tromethamine (30 mg)
Study: 6349780
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by adjuvant chemotherapy (5-FU and methyl-CCNU)
Study: 31204040
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (IANB injection with 2% lidocaine)
Study: 25730446
Drug: Medical honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical honey gel
Study: 17402274
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg once daily for 8 weeks
Study: 17402274
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg once daily for 8 weeks
Study: 15613923
Drug: FoodState Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FoodState Vitamin C complex (500 mg vitamin C, 160 mg bioflavonoids, 600 mg magnesium and 900 mg vitamin B complex)
Study: 9150780
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg.kg‐1
Study: 9150780
Drug: Tramadol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 0.5 mg.kg‐1
Study: 9150780
Drug: Tramadol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 0.5 mg.kg‐1, 1 mg.kg‐1, and 2 mg.kg‐1
Study: 7715467
Drug: Estrogen-gestagen replacement
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-gestagen replacement therapy
Study: 3233896
Drug: Intravenous piggyback
Normalized name: intravenous piggyback set MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous piggyback method
Study: 23669515
Drug: FITNET (Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: FITNET (Internet-based cognitive behavioral therapy)
Study: 21989146
Drug: LOAD-10 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LOAD-10 therapy (levofloxacin 250 mg, omeprazole 40 mg, nitazoxanide 500 mg twice daily, doxycycline 100 mg) for 10 days
Study: 21989146
Drug: LOAD-7 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOAD-7 therapy (levofloxacin 250 mg, omeprazole 40 mg, nitazoxanide 500 mg twice daily, doxycycline 100 mg) for 7 days
Study: 21989146
Drug: Combined LOAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined LOAD therapies
Study: 21989146
Drug: LAC therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg) for 10 days
Study: 16470745
Drug: Paclitaxel, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, 200 mg/m² IV, every 21 days for a minimum of four cycles
Study: 11588321
Drug: abciximab (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (0.25 mg/kg bolus before the lesion was crossed with guidewire and 0.125 micro. kg(‐1). min(‐1) infusion for 12 hours)
Study: 7862710
Drug: Naloxone (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.01, 0.1, 1.0 mg/70 kg)
Study: 7862710
Drug: Naloxone (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.0, 3.0, 10 mg/70 kg)
Study: 2512175
Drug: Rhein (diacetyl‐rhein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhein (diacetyl‐rhein 50 mg b.d. for 5 days)
Study: 8257478
Drug: 5'-MTHF (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-MTHF (50 mg/day p.o.)
Study: 8257478
Drug: Trazodone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (100 mg/day p.o.)
Study: 3582469
Drug: Urapidil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil infusion at 10 mg/h for 4 h
Study: 3582469
Drug: Urapidil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil infusion at 2.5 mg/h for 4 h
Study: 3582469
Drug: Urapidil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil infusion at 5 mg/h for 4 h
Study: 3582469
Drug: Urapidil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil infusion at 10 mg/h followed by a 60 mg capsule after 2 h
Study: 23176073
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg rasagiline
Study: 23176073
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg rasagiline and 1.5 mg pramipexole
Study: 20885016
Drug: Pentazocine 0.5
Normalized name: naloxone-pentazocine 0.5 mg-50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 0.5 mg·kg(‐1) 5 min prior to fentanyl
Study: 8776692
Drug: Standard osmolality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard osmolality feeding (1200 mOsmol/L)
Study: 8776692
Drug: High osmolality
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High osmolality feeding (1700 mOsmol/L)
Study: 1626958
Drug: Isotretinoin (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (approximately 0.14 mg/kg per day for 3 years)
Study: 6437509
Drug: Loperamide 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 0.8 mg/kg/24 h
Study: 6437509
Drug: Loperamide 0.4
Normalized name: loperamide 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 0.4 mg/kg/24 h
Study: 6437509
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral rehydration therapy
Study: 29421020
Drug: High-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen (10-15 L/min)
Study: 20970847
Drug: Aspirin (≥75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (≥75 mg daily)
Study: 20970847
Drug: Aspirin (75-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75-300 mg daily)
Study: 20970847
Drug: Aspirin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (30 mg vs 283 mg daily)
Study: 17284755
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 30 g dry weight of an iron-fortified cereal porridge and a separate dose of an aqueous multivitamin (MV) supplement
Study: 17284755
Drug: ZnSuppl group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnSuppl group: same porridge and MV with 3 mg Zn added to the supplement dose
Study: 17284755
Drug: ZnFort group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnFort group: porridge with added zinc (150 mg/kg dry weight) and MV without zinc
Study: 9049794
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Plak Control electric toothbrush